Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.